Ondansetron 8mg/mL

Injectable solution (IV or IM): Administer intravenously as a slow IV push over at least 30 seconds (preferably 2–5 minutes) or as an IV infusion diluted in compatible solution over 15 minutes. Intramuscular injection into a large muscle mass is an alternative when IV access is unavailable. Do not administer as rapid IV bolus — QTc prolongation and severe hypotension have been reported. Inspect visually for particulates and discoloration before use. Use aseptic technique at all times. Compatible with 0.9% NaCl and 5% dextrose for infusion dilution.

Dosing must be prescribed by the treating clinician. Established dosing frameworks for reference:

• Prevention of nausea/vomiting (PONV, chemotherapy-induced): 4–8 mg IV/IM as a single dose before the emetogenic stimulus; may be repeated every 4–8 hours for severe emesis.
• Hyperemesis gravidarum (off-label): 4–8 mg IV/IM per dose per prescriber protocol; typically reserved for cases refractory to first-line antiemetics.
• Pediatric: Weight-based dosing per prescriber order; pediatric doses are substantially lower than adult doses (typically 0.1 mg/kg IV, max 4 mg/dose in young children).
• Hepatic impairment (severe): Do not exceed 8 mg/day — reduced hepatic clearance significantly increases exposure.
• Final dose, frequency, and route are prescriber-determined.

• Ondansetron: Selectively and competitively antagonizes serotonin (5-hydroxytryptamine, 5-HT) at 5-HT3 receptors — ligand-gated ion channels found on vagal afferent neurons in the GI tract (enterochromaffin cells release 5-HT in response to cytotoxic stimuli or GI distension) and in the area postrema (chemoreceptor trigger zone) of the CNS. Blocking these receptors suppresses the afferent signals that initiate the vomiting reflex. Ondansetron has no significant dopaminergic, muscarinic, or histaminergic activity, which distinguishes its side-effect profile from older antiemetics.

Indications context: Ondansetron injectable is used for prevention and treatment of chemotherapy-induced nausea and vomiting (CINV), radiation-induced nausea and vomiting (RINV), postoperative nausea and vomiting (PONV), and off-label for hyperemesis gravidarum and acute gastroenteritis-related vomiting. The injectable form is particularly valuable when oral administration is not feasible.

Prescriber monitoring considerations:

• Baseline and periodic ECG in patients with cardiac risk factors, electrolyte abnormalities, or concomitant QT-prolonging medications; ondansetron prolongs the QTc interval in a dose-dependent manner.
• Correct hypokalemia and hypomagnesemia before administration to reduce arrhythmia risk.
• Serotonin syndrome: rare but potentially life-threatening; increased risk when combined with other serotonergic agents (SSRIs, SNRIs, MAOIs, tramadol).
• Monitor closely in patients with severe hepatic impairment; reduce dosing accordingly.
• Masking of progressive ileus: ondansetron's anti-emetic effect can mask worsening obstruction — assess bowel sounds and clinical status.

Contraindications:

• Hypersensitivity to ondansetron or other 5-HT3 receptor antagonists (cross-sensitivity possible)
• Concomitant use with apomorphine (profound hypotension and loss of consciousness reported)
• Congenital long QT syndrome

Warnings & Precautions:

• QTc prolongation and Torsades de Pointes: dose-dependent; avoid in patients with QTc >500 ms, electrolyte abnormalities, or concomitant QT-prolonging drugs
• Serotonin syndrome: particularly with high doses or co-administration of serotonergic drugs
• Severe hepatic impairment: maximum 8 mg/day total dose
• Masking of intestinal obstruction or gastric distension

Drug Interactions:

• Apomorphine: contraindicated — profound hypotension
• QT-prolonging agents (antiarrhythmics, antipsychotics, certain antibiotics): additive QTc prolongation risk
• SSRIs, SNRIs, fentanyl, tramadol, MAOIs: increased serotonin syndrome risk
• CYP3A4 and CYP2D6 inducers (rifampin, carbamazepine): may reduce ondansetron plasma levels

Common Side Effects: Headache, constipation, transient elevation of liver transaminases, injection site reactions (IM), and mild dizziness.

Store compounded ondansetron injectable solution at controlled room temperature (20–25°C / 68–77°F) or refrigerated (2–8°C) per label directions, protected from light. Do not freeze. Inspect for particulate matter and discoloration before use; discard if either is observed. Beyond-use date is assigned by Genesis Compounding and appears on the label. Use aseptic technique when withdrawing doses. Discard any unused portion per applicable regulations.

Why is this given as an injection rather than a tablet?

When a patient is actively vomiting, oral or sublingual medications may not be reliably absorbed. Injectable ondansetron provides rapid, predictable systemic delivery bypassing the GI tract, making it the preferred route in perioperative, chemotherapy, or hyperemesis settings.

How quickly does this take effect?

IV ondansetron reaches peak plasma concentration within minutes. Antiemetic effect is typically evident within 30 minutes of administration, with duration of 4–8 hours depending on the emetogenic stimulus and individual pharmacokinetics.

Does ondansetron affect the heart?

Yes — ondansetron can prolong the QT interval on electrocardiogram in a dose-dependent manner. This is why your prescriber may check an ECG, electrolytes (especially potassium and magnesium), and your full medication list before ordering this medication. Rapid IV push is avoided for this reason.

Is this safe during pregnancy?

Ondansetron is used off-label for hyperemesis gravidarum; its use in pregnancy — particularly the first trimester — has been studied, with most data not showing a significant increase in major malformations, though some studies have raised questions. This is a decision made by the prescribing obstetrician weighing individual clinical risk and benefit.

Is this FDA-approved?

Ondansetron is FDA-approved in various commercial forms. This compounded injectable preparation is a prescriber-directed, patient-specific 503A formulation prepared by Genesis Compounding; it is not FDA-approved as a compounded product.